Trial Outcomes & Findings for Initial Performance of a Daily Disposable Contact Lens Featuring Molded Marks (NCT NCT02939170)

NCT ID: NCT02939170

Last Updated: 2018-07-02

Results Overview

An AE was defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs in subjects, users or other persons, whether or not related to the investigational medical device (test article). Ocular discomfort device-related AE was defined as an ocular AE classified as "Related" to study device and deemed to be related to ocular discomfort.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

87 participants

Primary outcome timeframe

Day 1 at Hour 9

Results posted on

2018-07-02

Participant Flow

Subjects were recruited from 5 study centers located in the United States.

Of the 87 enrolled, 7 subjects were exited as screen failures prior to randomization. This reporting group includes all randomized subjects (80).

Participant milestones

Participant milestones
Measure
DT1 MF MM
Delefilcon A multifocal contact lenses with molded marks on back surface worn bilaterally (in both eyes) for 9 hours
DT1 MF
Delefilcon A multifocal contact lenses worn bilaterally for 9 hours
Overall Study
STARTED
40
40
Overall Study
COMPLETED
40
40
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Initial Performance of a Daily Disposable Contact Lens Featuring Molded Marks

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
DT1 MF MM
n=40 Participants
Delefilcon A multifocal contact lenses with molded marks on back surface worn bilaterally for 9 hours
DT1 MF
n=40 Participants
Delefilcon A multifocal contact lenses worn bilaterally for 9 hours
Total
n=80 Participants
Total of all reporting groups
Age, Continuous
36.2 years
STANDARD_DEVIATION 9.47 • n=99 Participants
36.1 years
STANDARD_DEVIATION 10.07 • n=107 Participants
36.2 years
STANDARD_DEVIATION 9.71 • n=206 Participants
Sex: Female, Male
Female
31 Participants
n=99 Participants
28 Participants
n=107 Participants
59 Participants
n=206 Participants
Sex: Female, Male
Male
9 Participants
n=99 Participants
12 Participants
n=107 Participants
21 Participants
n=206 Participants

PRIMARY outcome

Timeframe: Day 1 at Hour 9

Population: Safety Analysis Set

An AE was defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs in subjects, users or other persons, whether or not related to the investigational medical device (test article). Ocular discomfort device-related AE was defined as an ocular AE classified as "Related" to study device and deemed to be related to ocular discomfort.

Outcome measures

Outcome measures
Measure
DT1 MF MM
n=80 Eyes
Delefilcon A multifocal contact lenses with molded marks on back surface worn bilaterally for 9 hours
DT1 MF
n=80 Eyes
Delefilcon A multifocal contact lenses worn bilaterally for 9 hours
Incidence of Ocular Discomfort Device-related Adverse Events (AE)
0 Events
1 Events

SECONDARY outcome

Timeframe: Day 1 at Hour 9

Population: Safety Analysis Set

Assessed by the Investigator through slit-lamp examination and graded on a 5-point scale, where 0=none and 4=severe. Ocular staining was categorized by corneal staining, conjunctival staining, and limbal staining. Both eyes contributed to the analysis.

Outcome measures

Outcome measures
Measure
DT1 MF MM
n=80 Eyes
Delefilcon A multifocal contact lenses with molded marks on back surface worn bilaterally for 9 hours
DT1 MF
n=80 Eyes
Delefilcon A multifocal contact lenses worn bilaterally for 9 hours
Ocular Staining
Corneal Staining, Grade 0
62 Eyes
63 Eyes
Ocular Staining
Corneal Staining, Grade 1
14 Eyes
17 Eyes
Ocular Staining
Corneal Staining, Grade 2
4 Eyes
0 Eyes
Ocular Staining
Corneal Staining, Grade 3
0 Eyes
0 Eyes
Ocular Staining
Corneal Staining, Grade 4
0 Eyes
0 Eyes
Ocular Staining
Conjunctival Staining, Grade 0
60 Eyes
61 Eyes
Ocular Staining
Conjunctival Staining, Grade 1
15 Eyes
15 Eyes
Ocular Staining
Conjunctival Staining, Grade 2
5 Eyes
4 Eyes
Ocular Staining
Conjunctival Staining, Grade 3
0 Eyes
0 Eyes
Ocular Staining
Conjunctival Staining, Grade 4
0 Eyes
0 Eyes
Ocular Staining
Limbal Staining, Grade 0
72 Eyes
67 Eyes
Ocular Staining
Limbal Staining, Grade 1
7 Eyes
13 Eyes
Ocular Staining
Limbal Staining, Grade 2
1 Eyes
0 Eyes
Ocular Staining
Limbal Staining, Grade 3
0 Eyes
0 Eyes
Ocular Staining
Limbal Staining, Grade 4
0 Eyes
0 Eyes

SECONDARY outcome

Timeframe: Day 1 at Hour 9

Population: Safety Analysis Set

Hyperemia (excess of blood) was assessed by the Investigator through slit-lamp examination and graded on a 5-point scale, where 0=none and 4=severe. Both eyes contributed to the analysis.

Outcome measures

Outcome measures
Measure
DT1 MF MM
n=80 Eyes
Delefilcon A multifocal contact lenses with molded marks on back surface worn bilaterally for 9 hours
DT1 MF
n=80 Eyes
Delefilcon A multifocal contact lenses worn bilaterally for 9 hours
Limbal Hyperemia
Grade 2
0 Eyes
1 Eyes
Limbal Hyperemia
Grade 3
0 Eyes
0 Eyes
Limbal Hyperemia
Grade 4
0 Eyes
0 Eyes
Limbal Hyperemia
Grade 0
60 Eyes
52 Eyes
Limbal Hyperemia
Grade 1
20 Eyes
27 Eyes

Adverse Events

Pre-treatment

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

DT1 MF MM

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

DT1 MF

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Clinical Project Lead, Clinical Affairs

Alcon, A Novartis Division

Phone: 1-888-451-3937

Results disclosure agreements

  • Principal investigator is a sponsor employee Sponsor reserves the right of prior review of any publication or presentation of information related to the study.
  • Publication restrictions are in place

Restriction type: OTHER